12/23
08:57 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
12/6
08:06 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
12/2
04:30 pm
jspr
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
Low
Report
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
11/16
09:56 am
jspr
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate [Yahoo! Finance]
11/16
01:39 am
jspr
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
Medium
Report
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
11/13
04:30 pm
jspr
Jasper Therapeutics to Participate at Upcoming Investor Conferences
Medium
Report
Jasper Therapeutics to Participate at Upcoming Investor Conferences
11/7
07:30 am
jspr
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/24
08:08 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
10/24
08:00 am
jspr
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Medium
Report
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
10/23
08:00 am
jspr
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
Low
Report
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
10/15
12:31 pm
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
10/15
08:47 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
10/14
07:00 am
jspr
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
High
Report
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
9/27
11:05 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.